Staar Surgical Company (STAA)
Staar Surgical (STAA) Reports Q1 Loss, Tops Revenue Estimates
Staar Surgical (STAA) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to earnings of $0.06 per share a year ago.
STAAR Surgical Company (STAA) Q4 2024 Earnings Call Transcript
STAAR Surgical Company (NASDAQ:STAA ) Q4 2024 Earnings Call Transcript February 11, 2025 5:00 PM ET Company Participants Brian Moore - VP, Investor Relations and Corporate Development Tom Frinzi - Chair of the Board, President and CEO Patrick Williams - CFO Conference Call Participants Iseult Mcmahon - BTIG Tom Stephan - Stifel Anthony Petrone - Mizuho Macauley Kilbane - William Blair Patrick Wood - Morgan Stanley Steve Lichtman - Oppenheimer Jim Sidoti - Sidoti & Co. Phillip Dantoin - Piper Sandler Jon Young - Canaccord David Saxon - Needham & Co. Mason Carrico - Stephens Operator Greetings and welcome to the STAAR Surgical Fourth Quarter 2024 Earnings Webcast. As a reminder, this event is being recorded today Tuesday, February 11th, 2025.
STAAR Surgical Q4: Ongoing Challenges In China Masks Healthy Growth Elsewhere
STAAR Surgical's Q4 results were severely impacted by lower demand and high inventory levels in China. Global growth ex-China was 17% in Q4 and is expected to remain strong at 12% for FY25, with US growth of close to 15%. Cash burn is expected to be significant, but the company is financially healthy, having $232 million in cash and no debt on its balance sheet.
STAAR Surgical: Growth Story Remains Intact Despite Some Challenges
Shares have been under pressure lately due to weak demand from China, which is by far the company's largest market. The market opportunity in the US remains large, and management is investing heavily to tap into it. I have modest expectations for overall growth in FY25 of 9%, with markets excluding China growing significantly faster.
A Dive into Staar Surgical (STAA) International Revenue Trends and Forecasts
Evaluate Staar Surgical's (STAA) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
STAAR Surgical Company (STAA) Q3 2024 Earnings Call Transcript
STAAR Surgical Company (NASDAQ:STAA ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Brian Moore - VP, IR Tom Frinzi - Chair, President and CEO Patrick Williams - CFO Conference Call Participants Tom Stephan - Stifel Ryan Zimmerman - BTIG Patrick Wood - Morgan Stanley Operator Greetings and welcome to the STAAR Surgical Third Quarter 2024 Earnings Webcast. As a reminder, this event is being recorded today Wednesday, October 30th, 2024.
Staar Surgical (STAA) Surpasses Q3 Earnings and Revenue Estimates
Staar Surgical (STAA) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.30 per share a year ago.
Here's Why Staar Surgical (STAA) Could be Great Choice for a Bottom Fisher
Staar Surgical (STAA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Fast Money traders share their favorite stocks of the week
Fast Money traders Steve Grasso, Tim Seymour, Julie Biel, and Mike Khouw share their favorite stocks from this week and explain the reasoning behind their choices.
Wall Street Analysts Predict a 43.93% Upside in Staar Surgical (STAA): Here's What You Should Know
The mean of analysts' price targets for Staar Surgical (STAA) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Staar Surgical (STAA) Moves to Buy: Rationale Behind the Upgrade
Staar Surgical (STAA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
STAAR Surgical: Expecting A Re-Acceleration In Growth As Investments Materialize
STAAR Surgical shares are down more than 15% since Q2 earnings, despite management raising full-year revenue guidance. Investments in the US market appear to be yielding promising results, as sales were up 25% year over year. According to my estimates, the company is on track to meet the low end of its 2026 financial targets.
